The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Abbvie wants to notify you that effective May 18 2023 IMBRUVICA® (ibrutinib) US Prescribing Information has been updated and effective May 18 2023 IMBRUVICA® 560 mg tablet formulation has been voluntarily withdrawn from the market.

Product: IMBRUVICA® (ibrutinib) 560 mg tablet

NDC: 57962-560-28